My AccountLog in

1 option

Clinical review report : (Ipsen Biopharmaceuticals Canada, Inc.). AbobotulinumtoxinA (Dysport therapeutic) / Canadian Agency for Drugs and Technologies in Health.

NCBI BookshelfAvailable online

View online
Format:
Book
Author/Creator:
Canadian Agency for Drugs and Technologies in Health, author, issuing body.
Language:
English
Subjects (All):
Cost effectiveness.
Physical Description:
1 online resource (17 pages) : illustrations
Place of Publication:
Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2017.
Summary:
AbobotulinumtoxinA (aboBoNTA, Dysport Therapeutic) is a botulinum neurotoxin subtype indicated for the symptomatic treatment of focal spasticity affecting the upper limbs in adults (upper limb spasticity, ULS), and is available in single-use vials of 300 Units (U) and 500 U, at submitted prices of 28.40 and 14.00, respectively. The recommended initial dose of aboBoNTA is individually tailored depending on the size, number, and location of muscles involved. In the pivotal trial, 500 U or 1,000 U were used intramuscularly, divided among selected muscles, at a given treatment session. Repeat treatment should be administered when the effect of a previous injection has diminished, but no sooner than 12 weeks after the previous injection, with a majority of study patients being re-treated between 12 and 16 weeks. The manufacturer is requesting that aboBoNTA be reimbursed for the treatment of adults with focal spasticity, including spasticity of the upper limbs. CADTH Common Drug Review (CDR) previously reviewed aboBoNTA for the treatment of cervical dystonia; CADTH Canadian Drug Expert Committee recommended aboBoNTA be reimbursed in a manner similar to other botulinum neurotoxin A (BoNTA) therapies, and with a price reduction.
Notes:
Description based on publisher supplied metadata and other sources.

The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.

Find

HomeRelease notes

My Account

ShelfRequest an itemBookmarksFines and feesSettings

Guides

Using the Find catalogUsing Articles+Using your account